Ovid Therapeutics Inc (OVID) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.084x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.59 Million) by net assets ($209.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ovid Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Ovid Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Ovid Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Kelida Bldg &
SHG:603828
|
0.085x |
|
First Foundation Inc.
NYSE:FFWM
|
-0.027x |
|
Irish Residential Properties
IR:IRES
|
0.019x |
|
MPS Limited
NSE:MPSLTD
|
0.176x |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
0.119x |
|
Qingdao Copton Technology Co Ltd
SHG:603798
|
0.016x |
|
Wajax Corporation
TO:WJX
|
0.026x |
|
Masoval AS
OL:MAS
|
0.159x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2025. View Ovid Therapeutics Inc (OVID) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.66 Million | $-38.33 Million | -0.293x | +64.23% |
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more